MDM2 and hepatocellular carcinoma: In HCC ATR mutations have been reported anecdotally.[7] Based on preclinical evidence, ATR-deficient tumors may be sensitive to PARP inhibitors.[9] MDM2 acts to prevent the activity of the tumor suppressor p53; therefore, amplification of MDM2 may be oncogenic (Figure 2).